ALX Oncology Holdings Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| ALX Oncology Holdings Inc. | ALXO - NASDAQ |
$15.00-$17.00 | $19.00 | $36.50 | 8.5 million | 7/17/2020 |
| Jefferies, Credit Suisse, Piper Sandler, Cantor | ||||||
Co-Manager(s): LifeSci Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-06-26 Terms Added 2020-07-13 | ||||||
ALX Oncology Holdings Inc. Quote & Chart - Click for current quote - ALXO
IPO Boutique aggregates information on public companies and private companies, such as "ALXO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About ALX Oncology Holdings Inc. (adapted from ALX Oncology Holdings Inc. prospectus):
They are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ALXO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.